A Phase II Study of Chemotherapy Combined with Tyrosine Kinase Inhibitors for Children with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (JPLSG ALL-Ph13).

A Phase II Study of Chemotherapy Combined with Tyrosine Kinase Inhibitors for Children with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (JPLSG ALL-Ph13). - A Phase II Study of Chemotherapy with TKI for Children with Ph+ALL (JPLSG ALL-Ph13).

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011946

Enrollment

Registered

2013-10-02

Start date

2013-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Interventions

Chemotherapy combined with imatinib or dasatinib.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) diagnosis of Ph+ALL 2) age between 1 and 19 years old 3) ECOG performance status (PS) score of 0-3 4) no history of previous chemotherapy or radiation therapy 5) written informed consent obtained from patient or guardians.

Exclusion criteria

Exclusion criteria: 1) uncontrolled infection, including active tuberculosis and positive of HIV antibody. 2) pregnancy or high possibility of pregnancy and giving suck wiman. 3) history of congenital or acquired immunodeficiency. 4) any inappropriate status judged by physician.

Design outcomes

Primary

Measure	Time frame
Three years event free survival	—

Countries

Japan

Contacts

Public ContactHirohide Kawasaki

Kansai Medical University Department of Pediatrics

kawasaki@hirakata.kmu.ac.jp072-804-0101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026